Gossamer Bio
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Gossamer Bio
Gossamer Bio, Inc. 是一家臨床階段的生物製藥公司，專注於在美國發現、獲取、開發和商業化免疫學、炎症和腫瘤學等疾病領域的療法。公司正在開發 GB002，一種吸入式小分子血小板衍生生長因子受體，或 PDGFR，集落刺激因子 1 受體，或 CSF1R，以及用於治療肺動脈高壓的 c-KIT 抑製劑； GB004，一種用於治療炎症性腸病的腸道靶向口服小分子藥物； GB5121，一種用於治療原發性中樞神經系統淋巴瘤的口服不可逆共價小分子佈魯頓酪氨酸激酶抑製劑； GB7208，一種用於治療多發性硬化症的口服小分子 BTK 抑製劑。它與 Pulmokine, Inc .簽訂了開發和商業化 GB002 和相關備用化合物的許可協議；和 Aerpio Pharmaceuticals, Inc. 開發和商業化 GB004 及相關化合物。公司前身為 FSG, Bio, Inc.，2017 年更名為 Gossamer Bio, Inc.。Gossamer Bio, Inc. 成立於 2015 年，總部位於加利福尼亞州聖地亞哥。
如何購買 Gossamer Bio (GOSS)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 GOSS
透過 RockFlow App 或網頁端搜尋 GOSS，輸入您想要投資的金額，然後點擊確認即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.